Evaluation of [(225)Ac]Ac-PSMA-617 vis-a-vis Rechallenge [(177)Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.
- DOI
- 10.1002/pros.70228
- Published
- 2026 Oct
- Container
- The Prostate
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/pros.70228,
title = {Evaluation of [(225)Ac]Ac-PSMA-617 vis-a-vis Rechallenge [(177)Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.},
author = {Agrawal R and Parghane RV and Joshi A and Prabhash K and Basu S},
year = {2026},
journal = {The Prostate},
doi = {10.1002/pros.70228},
url = {https://doi.org/10.1002/pros.70228}
}RIS
TY - JOUR TI - Evaluation of [(225)Ac]Ac-PSMA-617 vis-a-vis Rechallenge [(177)Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario. AU - Agrawal R AU - Parghane RV AU - Joshi A AU - Prabhash K AU - Basu S PY - 2026 JO - The Prostate DO - 10.1002/pros.70228 UR - https://doi.org/10.1002/pros.70228 ER -
APA
R, A., RV, P., A, J., K, P., & S, B. (2026). Evaluation of [(225)Ac]Ac-PSMA-617 vis-a-vis Rechallenge [(177)Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.. The Prostate. https://doi.org/10.1002/pros.70228
Source records
- pubmed · retrieved 2026-09-26T16:04:30.130Z